Medical equipment and services company Steris (NYSE:STE). in Q4 CY2024, but sales rose 5.6% year on year to $1.37 billion.

Total revenue fromcontinuing operations increased 6%; constant currency organic revenue grew 6% As reported diluted EPS from continuing ...

Steris this week announced that its jury trial against its subsidiary Isomedix Operations ended in a mistrial.

The sterilizer can be ordered with one of two door configurations. 1220 mm and 1520 mm configurations include choice of a single or double door. 910 mm configuration provides single door, only.

Steris said the trial against its Isomedix subsidiary was dismissed and will be rescheduled for a later date. The Irish medical-device company said the case, which began on Dec. 4, was declared a ...

STERIS plc (NYSE:STE), a leading provider of infection prevention and procedural products and services with a market capitalization of $21.6 billion, has been navigating a dynamic healthcare landscape ...

DUBLIN, IRELAND, Jan. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that a jury trial that had been ongoing since December 4, 2024, against Isomedix ...

STERIS (NYSE:STE – Get Free Report) had its target price upped by analysts at Piper Sandler from $260.00 to $265.00 in a ...

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization ...

laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company or BD. The acquisition strengthens, complements and expands STERIS’ Healthcare product ...

Pacer Advisors Inc. lessened its holdings in STERIS plc (NYSE:STE – Free Report) by 20.8% during the fourth quarter, ...